Soria Federico, de La Cruz Julia E, Fernandez Tomás, Budia Alberto, Serrano Álvaro, Sanchez-Margallo Francisco M
Endourology Department, Jesús Usón Minimally Invasive Surgery Centre Foundation, Cáceres, Spain.
Urology Department, University Hospital Morales Meseguer, Murcia, Spain.
Transl Androl Urol. 2021 Apr;10(4):1700-1710. doi: 10.21037/tau-21-19.
We assessed an antireflux biodegradable heparin-coated ureteral stent (BraidStent-H) in an animal model comparative study after endoscopic treatment of ureteral strictures.
A total of 24 female pigs underwent initial endoscopic, nephrosonographic, and contrast fluoroscopy assessment of the urinary tract. Afterward, unilateral laparoscopic ureteral stricture model was performed. Three weeks later, the animals underwent laser endoureterotomy and were randomly assigned to Group-I, in which a double-pigtail stent was placed for 6 weeks, or Group-II, in which a BraidStent®-H was placed. Follow-up was carried out by ultrasonography, contrast fluoroscopy, ureteroscopy, urinalysis and bacteriuria assessment at 3, 6, 12 and 5 months. Finally, a pathological study of the urinary system was performed.
There were no animals in Group-II with vesicoureteral reflux, with significance at 6 weeks with Group-I. Distal ureteral peristalsis was maintained in 50-75% in Group-II at 1-6 weeks. The 91.7% of stents in Group-II were degraded between 3-6 weeks, without obstructive fragments. Bacteriuria in Group II was 33.3-50% at 3 and 6 weeks. The global success rate by groups was 91.6% and 87.5% in groups I and II, respectively, with no statistical significance.
BraidStent-H has been shown to be as efficacious as current ureteral stents in the treatment of benign ureteral strictures following laser endoureterotomy. In addition, it reduces the morbidity associated with current stents and has a homogeneous and predictable degradation rate of about 6 weeks, with no obstructive fragments. Future studies are required to improve the antibacterial coating to reduce BraidStent-H contamination in view of the results obtained with the heparin coating.
在内镜治疗输尿管狭窄后的动物模型对比研究中,我们评估了一种抗反流可生物降解的肝素涂层输尿管支架(BraidStent-H)。
总共24只雌性猪接受了泌尿系统的初始内镜、肾超声和造影荧光透视评估。之后,建立单侧腹腔镜输尿管狭窄模型。三周后,动物接受激光输尿管内切开术,并随机分为两组:第一组放置双猪尾支架6周;第二组放置BraidStent®-H支架。在3、6、12和5个月时通过超声、造影荧光透视、输尿管镜检查、尿液分析和菌尿评估进行随访。最后,对泌尿系统进行病理研究。
第二组没有动物发生膀胱输尿管反流,在6周时与第一组相比具有显著差异。在第1至6周,第二组50%-75%的输尿管远端蠕动得以维持。第二组91.7%的支架在3至6周内降解,无阻塞性碎片。第二组在3周和6周时的菌尿率为33.3%-50%。两组的总体成功率分别为91.6%和87.5%,无统计学意义。
已证明BraidStent-H在激光输尿管内切开术后治疗良性输尿管狭窄方面与目前的输尿管支架同样有效。此外,它降低了与现有支架相关的发病率,具有约6周的均匀且可预测的降解率,无阻塞性碎片。鉴于肝素涂层的结果,未来需要进行研究以改进抗菌涂层,减少BraidStent-H的污染。